.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
US Army
Moodys
Healthtrust
Accenture
Medtronic
Harvard Business School
Merck
Cerilliant
Fuji

Generated: September 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Progenitor cells from Wharton\'s jelly of human umbilical cord
Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbors osteogenic progenitor cells and MHC-/- progenitor cells, and is useful to grow and repair human tissues including bone.
Inventor(s): Davies; John E. (Toronto, CA), Baksh; Dolores (Mississauga, CA), Sarugaser; Rahul (Toronto, CA), Hosseini; Morris (Braunschweig, DE), Lickorish; Antony D. S. (Toronto, CA)
Assignee: Tissue Regeneration Therapeutics Inc. (Toronto, CA)
Application Number:13/903,575
Patent Claims:1. A method for producing a differentiated cell capable of forming a tissue selected from bone, fat, cartilage, tendon, and muscle comprising culturing a cell population comprising human umbilical cord perivascular cells (HUCPVCs) with an agent that affects the differentiation thereof, wherein said HUCPVCs have a 3G5+, CD45-, CD44+ phenotype and said cell population is characterized by rapid proliferation and the presence of human progenitor cells, and wherein said culturing promotes the differentiation of said progenitor cells into said differentiated cell.

2. The method of claim 1, wherein said differentiated cell is a capable of forming bone.

3. The method of claim 1, wherein said differentiated cell is a capable of forming fat.

4. The method of claim 1, wherein said differentiated cell is a capable of forming cartilage.

5. The method of claim 1, wherein said differentiated cell is a capable of forming tendon.

6. The method of claim 1, wherein said differentiated cell is a capable of forming muscle.

7. The method of claim 1, wherein said cell population comprises cells that are negative for markers of MHC class I and MHC class II.

8. The method of claim 1, wherein said cell population is obtained from the perivascular region of at least one human umbilical cord blood vessel.

9. The method of claim 8, wherein the cell population is essentially free from cells derived from the vascular structure of the cord.

10. The method of claim 8, wherein said cell population is obtained by subjecting the umbilical cord blood vessel to enzymatic digestion in a suitable cell extraction medium.

11. The method of claim 10, wherein said enzymatic digestion is performed using collagenase.

12. The method of claim 1, wherein said cell population comprises cells further characterized by expression of one or more of the following markers: CD34-, SH2+, SH3+, Thy1+, alpha-actin+, desmin+, and vimentin+.

13. The method of claim 1, wherein said progenitor cells are osteoprogenitor cells, chondrogenic progenitor cells, adipogenic progenitor cells, or myogenic progenitor cells.

14. The method of claim 1, wherein said progenitor cells are capable of differentiating into bone, fat, cartilage, tendon, or muscle producing cells.

15. The method of claim 1, further comprising, prior to culturing with said agent, culturing said cell population to expand the population thereof.

16. The method of claim 1, further comprising preparing a composition comprising said differentiated cell for transplantation into a subject in need thereof.

17. The method of claim 16, wherein said composition comprises an amount of from 10.sup.3 to 10.sup.7 cells.

18. The method of claim 16, wherein said composition comprises a carrier.

19. The method of claim 18, wherein said carrier is selected from calcium phosphate, poly(lactic-co-glycolic acid) (PLGA), phosphate buffered saline, a gel, gelatin, or a mixture thereof.

20. The method of claim 1, wherein one or more cells in said cell population or said differentiated cell is genetically engineered to express a gene.

21. The method of claim 20, wherein said gene encodes a growth factor.

22. The method of claim 21, wherein said growth factor is selected from one or more of parathyroid hormone (PTH), bone morphogenetic protein (BMP), and calcitonin.

23. The method of claim 2, wherein said agent is selected from one or more of dexamethasone, .beta.-glycerophosphate, and ascorbic acid.

24. The method of claim 3, wherein said agent is selected from one or more of biotin, pantothenate, insulin, dexamethasone, and peroxisome proliferator-activated receptor gamma (PPAR-.gamma.).

25. The method of claim 4, wherein said agent is selected from one or more of transforming growth factor-.beta. and dexamethasone.

26. The method of claim 6, wherein said agent is hydrocortisone.

27. A method for producing connective tissue comprising culturing a cell population comprising human umbilical cord perivascular cells (HUCPVCs) with an agent that promotes formation of the connective tissue, wherein said HUCPVCs have a 3G5+, CD45-, CD44+ phenotype and the cell population is characterized by rapid proliferation and the presence of human progenitor cells.

28. The method of claim 27, wherein said connective tissue is selected from the group consisting of bone, fat, cartilage, tendon, and muscle.

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Nps Pharms Inc
NATPARA
parathyroid hormone
INJECTABLE;INJECTION1255110012015-01-23► Subscribe Tissue Regeneration Therapeutics Inc. (Toronto, CA) Davies; John E. (Toronto, CA), Baksh; Dolores (Mississauga, CA), Sarugaser; Rahul (Toronto, CA), Hosseini; Morris (Braunschweig, DE), Lickorish; Antony D. S. (Toronto, CA) ► SubscribeRXOrphansearch
Nps Pharms Inc
NATPARA
parathyroid hormone
INJECTABLE;INJECTION1255110022015-01-23► Subscribe Tissue Regeneration Therapeutics Inc. (Toronto, CA) Davies; John E. (Toronto, CA), Baksh; Dolores (Mississauga, CA), Sarugaser; Rahul (Toronto, CA), Hosseini; Morris (Braunschweig, DE), Lickorish; Antony D. S. (Toronto, CA) ► SubscribeRXOrphansearch
Nps Pharms Inc
NATPARA
parathyroid hormone
INJECTABLE;INJECTION1255110032015-01-23► Subscribe Tissue Regeneration Therapeutics Inc. (Toronto, CA) Davies; John E. (Toronto, CA), Baksh; Dolores (Mississauga, CA), Sarugaser; Rahul (Toronto, CA), Hosseini; Morris (Braunschweig, DE), Lickorish; Antony D. S. (Toronto, CA) ► SubscribeRXOrphansearch
Nps Pharms Inc
NATPARA
parathyroid hormone
INJECTABLE;INJECTION1255110042015-01-23► Subscribe Tissue Regeneration Therapeutics Inc. (Toronto, CA) Davies; John E. (Toronto, CA), Baksh; Dolores (Mississauga, CA), Sarugaser; Rahul (Toronto, CA), Hosseini; Morris (Braunschweig, DE), Lickorish; Antony D. S. (Toronto, CA) ► SubscribeRXOrphansearch
Advance Biofactures
SANTYL
collagenase
VIAL1019950011965-06-04► Subscribe Tissue Regeneration Therapeutics Inc. (Toronto, CA) Davies; John E. (Toronto, CA), Baksh; Dolores (Mississauga, CA), Sarugaser; Rahul (Toronto, CA), Hosseini; Morris (Braunschweig, DE), Lickorish; Antony D. S. (Toronto, CA) ► SubscribeRXsearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
Austria478941Sep 15, 2010
Australia2004210891Aug 26, 2004
Australia2004210891Sep 25, 2008
Australia2008261123Jan 15, 2009
Australia2012227326Nov 19, 2015
Australia2012227326Oct 18, 2012
BrazilPI0407221Jan 31, 2006
Canada2515469Aug 26, 2004
Canada2515469Dec 17, 2013
Germany602004028803Oct 07, 2010
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Argus Health
AstraZeneca
Accenture
Cerilliant
Chinese Patent Office
Farmers Insurance
QuintilesIMS
McKesson
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot